Salinomycin

[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1

[1]Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108 (32) :13253-7.|[2]Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222 (2) :139-45.|[3]Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7 (12) : e50638.|[4]Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8 (7) :578-82.|[5]Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14 (2) :e0211916.|[6]Naujokat C, et al. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.

ACS Infect Dis. 2021 Aug 13;7 (8) :2390-2401.|Acta Biomater. 2022 Oct 15:152:380-392.|Adv Sci (Weinh) . 2025 Feb 8:e2415229.|Adv Sci (Weinh) . 2025 Sep 9:e13476.|Anal Chem. 2023 Apr 11;95 (14) :6191.|Biochim Biophys Acta Mol Cell Res. 2025 May 11:119989.|Biomed J. 2020 Aug;43 (4) :368-374.|bioRxiv. 2020 Jun.|bioRxiv. 2023 Jan 17.|bioRxiv. 2023 Jun 25.|bioRxiv. 2024 September 07.|bioRxiv. 2024 September 18.|Biosens Bioelectron. 2024 Jul 1:255:116245.|Cancers. 2020 Aug 5;12 (8) :2176.|Cell Biosci. 2021 Aug 4;11 (1) :156.|Cell Commun Signal. 2018 Nov 23;16 (1) :89.|Cell Death Dis. 2023 Mar 11;14 (3) :193.|Cell Oncol (Dordr) . 2024 Dec;47 (6) :2201-2215.|Chemosphere. 2024 Jul 3:142758.|EMBO Mol Med. 2019 Oct;11 (10) :e9930.|Eur J Med Chem. 2024 Oct 5:276:116701.|Eur J Pharmacol. 2025 Jul 5:998:177533.|Hepatol Commun. 2025 May 16;9 (6) :e0706.|Int J Mol Med. 2019 Oct;44 (4) :1289-1298.|Int J Mol Sci. 2019 Jun 12;20 (12) :2861.|Int J Mol Sci. 2023 Mar 21;24 (6) :5939.|Int J Nanomedicine. 2020 Sep 15;15:6839-6854.|J Bioenerg Biomembr. 2021 Oct;53 (5) :513-523.|J Control Release. 2020 Oct 10;326:387-395.|Mol Med. 2025 Jan 22;31 (1) :19.|Nanoscale. 2024 Nov 7;16 (43) :20131-20146.|Norwegian University of Science and Technology. Department of Clinical and Molecular Medicine. 2021 Oct.|Oncol Rep. 2018 Aug;40 (2) :877-886.|Pharmacol Res. 2020 May;155:104751.|RSC Adv. 2021 Nov 2;11 (56) :35331-35341.|Talanta. 2025 Apr 10:293:128128.|Viruses. 2022 Aug 6;14 (8) :1734.|AAPS PharmSciTech. 2024 Sep 7;25 (7) :211.|Cell Rep. 2025 Jul 22;44 (7) :115922.|Eur J Med Chem. 2024 Oct 5:276:116701.|Exp Ther Med. 2020 Mar;19 (3) :1835-1843.|Int J Pharm. 2023 Mar 25:635:122779.|Nat Commun. 2025 Jul 18;16 (1) :6621.|SSRN. 2024 Nov 12.